Seeking Alpha

Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, ...
Seeking Alpha

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023

CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, ...
WREG

Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab ...

– Management to host conference call to discuss SRF388 data and other corporate updates today at 8:30 a.m. ET – CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a ...
Nasdaq

Surface Oncology to Present Preclinical Data for Lead Clinical Programs at the Society for Immunotherapy of Cancer 2021 Annual Meeting

CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...
Business Insider

Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617

CAMBRIDGE, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...
Business Insider

Vaccinex, Inc. Announces Research Collaboration Employing ActivMAb® Platform Technology and Antibody License Option Agreement with Surface Oncology

ROCHESTER, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the development of therapeutic monoclonal antibodies to treat ...
Fox2Now St. Louis

Coherus Completes Surface Oncology Acquisition

REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the closing of the previously announced acquisition of Surface Oncology, Inc.
The Business Journals

Surface Oncology CEO Rob Ross returns, with new $150M-backed startup

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The new immuno-oncology company ...
Reuters

Novartis signs $170 million immuno-oncology pact with Surface

ZURICH (Reuters) - Novartis AG has struck a $170 million alliance with U.S.-based Surface Oncology as it seeks to boost its portfolio of medicines that help the body's immune system fight cancer. The ...
AOL

Analysts Just Made A Significant Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

Celebrations may be in order for Surface Oncology, Inc. (NASDAQ:SURF) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. Consensus estimates ...
WREG

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023

CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...